Treatment of acute renal allograft rejection with monoclonal anti-T12 antibody.
Nineteen patients with acute rejection of a renal allograft were treated with the monoclonal antibody anti-T12, directed against a determinant present on all post-thymic T cells. Seven patients had a good response, four had an equivocal response, and eight failed to respond. Histologic studies demonstrated that the good responders had primarily cellular rejection. The nonresponders included 4 patients with moderate-to-severe humoral rejection, one patient with an inadequate dose of antibody, one patient who withdrew before completing the study, and one patient with late end-stage rejection. All eleven patients with good or equivocal responses have functioning kidneys in a follow-up of 1-15 months (mean 7 months). Only one patient has had a subsequent acute rejection episode, which responded to a steroid pulse. No significant complications of anti-T12 therapy occurred.
D000328:Adult; D000911:Antibodies, Monoclonal / Q000276:immunology*; D002469:Cell Separation; D000939:Epitopes; D005260:Female; D005434:Flow Cytometry; D006084:Graft Rejection; D006801:Humans; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D013997:Time Factors; D014184:Transplantation, Homologous
D000911:Antibodies, Monoclonal; D000939:Epitopes